November 28, 2022 11:08 AM EST

Industry groups, CVS pick apart FDA's proposed pathway for generics to carve out OTC indications

Zachary Brennan

Senior Editor

Pharma industry groups like the Association for Accessible Medicines (AAM) and PhRMA are raising pointed questions about an FDA plan to create a new pathway …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Industry groups, CVS pick apart FDA's proposed pathway for generics to carve out OTC indications

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Exclusive: J&J folds cardiovascular and metabolic drug unit

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

In­dus­try groups, CVS pick apart FDA's pro­posed path­way for gener­ics to carve out OTC in­di­ca­tions

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Industry groups, CVS pick apart FDA's proposed pathway for generics to carve out OTC indications